QIAGEN enters into broad collaboration agreement with Lilly for the development and commercialization of companion diagnostics
. - Arrangement to facilitate future collaborations in personalized medicine - Provides framework to develop and comme…
. - Arrangement to facilitate future collaborations in personalized medicine - Provides framework to develop and comme…
. - Momentum builds for therascreen® KRAS RGQ PCR Kit and Rotor-Gene Q MDx instrument - Clarient offers network of 2,…
. QIAGEN exceeds Q4 and full-year 2012 targets: - Full-year 2012: Net sales advance 10% CER (+7% reported) to $1.…
. - U.S. submission of therascreen® EGFR RGQ PCR Kit is paired with FDA submission of afatinib, an investigational tyro…
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced today that it exceeded its goal for new placements o…
QIAGEN invests in new companion diagnostic being developed by Drug Response Dx that aims to predict efficacy of TNF-alph…
. - QIAGEN and Bayer HealthCare signed collaboration agreement aimed at advancing both companies positions in personali…
. - Solid performance in second quarter of 2012: Net sales rise 9% (+14% CER) to $307.2 million on growth in all custom…
. - U.S. launch of therascreen® KRAS RGQ PCR Kit offers enhanced approach to guide treatments for approximately 110,000…
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that Cardinal Health (NYSE: CAH) has extended…